Artikler med mandater om offentlig tilgang - Emanuel PetricoinLes mer
TotaltNIHDoDPancreatic Cancer Action Network, USAGovernment of ItalyDFGState of CalifoniaEuropean CommissionAIRC Foundation for Cancer Research in ItalySusan G. KomenNSFDOEGatesGenome CanadaHRBDoris Duke Charitable FoundationV Foundation, USASNSFVAHHMINHMRCCIHRNSFCINSERMA*StarMRCANRGovernment of SpainKWFLymphoma Research Foundation, USADamon Runyon Cancer Research FoundationMelanoma Research Alliance
Ikke tilgjengelige noe sted: 11
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
JD Wulfkuhle, R Speer, M Pierobon, J Laird, V Espina, J Deng, ...
Journal of proteome research 7 (4), 1508-1517, 2008
Mandater: US National Institutes of Health, German Research Foundation
Cancer metabolism and mass spectrometry-based proteomics
W Zhou, LA Liotta, EF Petricoin
Cancer letters 356 (2), 176-183, 2015
Mandater: US National Institutes of Health
Mass spectrometry-based biomarker discovery
W Zhou, EF Petricoin, C Longo
Molecular Profiling: Methods and Protocols, 297-311, 2017
Mandater: US National Institutes of Health, Government of Italy
Reverse phase protein microarrays: fluorometric and colorimetric detection
RI Gallagher, A Silvestri, EF Petricoin, LA Liotta, V Espina
Protein Microarray for Disease Analysis: Methods and Protocols, 275-301, 2011
Mandater: US National Institutes of Health
Reverse phase protein microarrays for clinical applications
M Pierobon, C Belluco, LA Liotta, EF Petricoin
Protein Microarrays: Methods and Protocols, 3-12, 2011
Mandater: US National Institutes of Health
Clinical application of proteomics in ovarian cancer prevention and treatment
F Meani, S Pecorelli, L Liotta, EF Petricoin
Molecular diagnosis & therapy 13, 297-311, 2009
Mandater: US National Institutes of Health
Endogenous gastrin collaborates with mutant KRAS in pancreatic carcinogenesis
S Nadella, J Burks, M Huber, J Wang, H Cao, B Kallakury, RD Tucker, ...
Pancreas 48 (7), 894-903, 2019
Mandater: US National Institutes of Health
Antitumor effect of insulin‐like growth factor‐1 receptor inhibition in head and neck squamous cell carcinoma
CE Lehman, AA Khalil, MJ Axelrod, MI Dougherty, SS Schoeff, ...
The Laryngoscope 130 (6), 1470-1478, 2020
Mandater: US National Institutes of Health
Mass spectrometry-based biomarker discovery
W Zhou, EF Petricoin, C Longo
Molecular Profiling: Methods and Protocols, 251-264, 2012
Mandater: US National Institutes of Health
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy
I Micaily, EM Blais, R Carhart, S Lam, SJ Cohen, SJ Cannaday, ...
JCO Precision Oncology 7, e2200648, 2023
Mandater: Pancreatic Cancer Action Network, USA
Development and pilot evaluation of a new nanoparticle-capture workflow for doxorubicin-induced toxicity biomarker identification
EF Petricoin, MM Ross, W Zhou, D Tamburro, A Luchini, LA Liotta, ...
Progress in Pediatric Cardiology 39 (2), 85-91, 2015
Mandater: US National Institutes of Health
Tilgjengelige et eller annet sted: 207
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 25 (4), 628-640, 2019
Mandater: US Department of Defense, US National Institutes of Health, German Research …
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
MJ Pishvaian, EM Blais, JR Brody, E Lyons, P DeArbeloa, A Hendifar, ...
The Lancet Oncology 21 (4), 508-518, 2020
Mandater: US National Institutes of Health, Pancreatic Cancer Action Network, USA
Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
AC Decarvalho, H Kim, LM Poisson, ME Winn, C Mueller, D Cherba, ...
Nature genetics 50 (5), 708-717, 2018
Mandater: US National Institutes of Health, Genome Canada
Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression
TK Hayes, NF Neel, C Hu, P Gautam, M Chenard, B Long, M Aziz, ...
Cancer cell 29 (1), 75-89, 2016
Mandater: US National Institutes of Health, Pancreatic Cancer Action Network, USA
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process
V Espina, KH Edmiston, M Heiby, M Pierobon, M Sciro, B Merritt, S Banks, ...
Molecular & cellular proteomics 7 (10), 1998-2018, 2008
Mandater: US National Institutes of Health
Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative
MJ Pishvaian, RJ Bender, D Halverson, L Rahib, AE Hendifar, S Mikhail, ...
Clinical Cancer Research 24 (20), 5018-5027, 2018
Mandater: Pancreatic Cancer Action Network, USA
Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?
V Fodale, M Pierobon, L Liotta, E Petricoin
The Cancer Journal 17 (2), 89-95, 2011
Mandater: US National Institutes of Health
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ...
Cancer cell 39 (7), 989-998. e5, 2021
Mandater: US National Institutes of Health
Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society
R Akbani, KF Becker, N Carragher, T Goldstein, L De Koning, U Korf, ...
Molecular & cellular proteomics 13 (7), 1625-1643, 2014
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram